Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Chugai to Enter Diabetes Field in Earnest
December 21, 2009
- Banyu Launches Japan's 1st DPP-4 Inhibitor Januvia
December 21, 2009
- Onbrez Breezhaler Approved for COPD in EU: Novartis
December 21, 2009
- GSK to Launch HPV Vaccine Cervarix
December 21, 2009
- Micardis Approved by EC for Reduction in CV Morbidity
December 21, 2009
- Nippon Chemiphar, Ranbaxy Terminate Alliance
December 21, 2009
- Bayer Schering Starts PIII Trial for Florbetaben
December 21, 2009
- Januvia Leaps to Top Place on GP Market: Rep Track Survey
December 21, 2009
- Dabigatran Shows Non-Inferiority to Warfarin: BI
December 21, 2009
- Wholesalers’Primary Profit on Sales -2.04% in FY2008: Mr Matsutani
December 21, 2009
- Sumitomo Chemical, Kracie to Codevelop Scabies Treatment
December 21, 2009
- Diversifying Business Not the Cure for “Patent Cliff”: Datamonitor
December 21, 2009
- BioComber Licenses Cell-Free Protein Synthesis Technology to Chugai
December 21, 2009
- Large Gap between Korosho's Proposals and MOF's Requirements
December 14, 2009
- Takeda Aims at Entering South American Generics Market
December 14, 2009
- Ordinary NHI Price Cut Rate in FY2010 Expected to Be 6.4%
December 14, 2009
- Otsuka Extends Research Collaboration with Galenea for 1 More Year
December 14, 2009
- Medical Fees Should Be Increased: Mr Sengoku
December 14, 2009
- Hisamitsu to Enhance Operation Efficiency in US
December 14, 2009
- NHI Price Listing OK'd for 23 Products, 12 APIs
December 14, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…